Assertio Holdings shares surge 10.04% intraday after Q3 2025 earnings highlight $49.5M sales growth and $20.9M adjusted EBITDA.

Assertio Holdings surged 10.04% intraday following its Q3 2025 earnings call, which highlighted robust financial performance. Total product sales rose to $49.5 million (from $28.7 million in Q3 2024), driven by a 43% market share for Rolvidon in Medicare Part B clinics. Adjusted EBITDA jumped to $20.9 million (from $4.4 million), supported by Rolvidon sales and a long-term supply agreement with Omni. The company also reported $93.4 million in cash equivalents, reinforcing financial stability. While the call noted near-term challenges like a temporary cash flow dip due to Rolvidon sales timing and declining Indocin sales, the immediate bullish reaction reflected confidence in sustained growth and strategic stability for key products. Executive comments on price predictability and digital promotion for Simpizan further reinforced positive sentiment.